These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38600747)

  • 1. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
    Yun X; Zhou Y; Wu D; Liu Y; Wu Q
    Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
    Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y
    Expert Opin Drug Saf; 2024 Jul; 23(7):905-916. PubMed ID: 38108285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database.
    Yao H; Wang Y; Peng Y; Huang Z; Gan G; Wang Z
    J Clin Pharmacol; 2024 Jul; 64(7):820-827. PubMed ID: 38375685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
    Shu Y; He X; Liu Y; Wu P; Zhang Q
    Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
    Zhu H; Wu M
    Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
    Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
    J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
    Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
    Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 17. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.
    Zhang X; Ren X; Zhu T; Zheng W; Shen C; Lu C
    Front Pharmacol; 2024; 15():1407709. PubMed ID: 39114350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.